Could a shot every 6 months end HIV? new study tests lenacapavir in south africa

NCT ID NCT07390409

Not yet recruiting Prevention Sponsor: Desmond Tutu HIV Foundation Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study will offer young people aged 15-35 in Cape Town a choice of HIV prevention methods: a new twice-yearly injection (lenacapavir), a two-monthly injection (cabotegravir), or daily pills. Researchers want to see which option people stick with over 18 months and how best to deliver these choices in clinics and mobile trucks. The goal is to make HIV prevention easier and more effective.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: lenacapavir injection
What this could lead to: If successful, this could provide a convenient twice-yearly injection that helps prevent HIV in young people, potentially improving adherence and reducing new infections.
What could go wrong: This is an early real-world study, not a large phase 3 trial. Results may not apply to other regions, and participants may still face side effects or injection-site reactions.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HIV are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

HIV infectious disease prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HIV

Contacts and locations

Locations

DTHF Mobile Clinics

Cape Town, WC, 7925, South Africa

More trials for these conditions

Other studies related to the condition(s) this trial covers.